4BASEBIO PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,160 GBX | +1.31% |
|
+7.41% | +70.59% |
| Apr. 10 | 4basebio to supply synthetic DNA for mRNA vaccine program | AN |
| Apr. 10 | 4Basebio plc Announces the Supply of Its opDNA? DNA Products into Tier 1 Pharma Client's Vaccine Program | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2021 | 338K 423K | Sales 2022 | 268K 336K | Capitalization | 87.45M 110M |
|---|---|---|---|---|---|
| Net income 2021 | -3M -3.76M | Net income 2022 | -5M -6.26M | EV / Sales 2021 | 200 x |
| Net cash position 2021 | 8.06M 10.09M | Net cash position 2022 | 1.24M 1.55M | EV / Sales 2022 | 322 x |
| P/E ratio 2021 |
-23.4
x | P/E ratio 2022 |
-17
x | Employees | 78 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 30.4% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.31% | ||
| 1 week | +7.41% | ||
| Current month | +8.41% | ||
| 1 month | +13.73% | ||
| 3 months | +60.00% | ||
| 6 months | +132.00% | ||
| Current year | +70.59% |
1 week
1 061.00
1 188.00
1 month
1 000.001 188.00
Current year
640.001 188.00
1 year
492.001 188.00
3 years
351.001 188.00
5 years
175.001 188.00
10 years
175.001 188.00
| Managers | Title | Age | Since |
|---|---|---|---|
Heikki Lanckriet
CEO | Chief Executive Officer | 46 | 20-12-21 |
David John Roth
DFI | Director of Finance/CFO | 56 | 20-12-21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Joseph Fernández
BRD | Director/Board Member | 64 | - |
David John Roth
DFI | Director of Finance/CFO | 56 | 20-12-21 |
| Director/Board Member | 53 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 1,160 | +1.31% | 2,186 |
| 24-05-09 | 1,145 | +5.05% | 2,394 |
| 24-05-08 | 1,090 | +0.93% | 2,456 |
| 24-05-07 | 1,080 | 0.00% | 1,170 |
Delayed Quote London S.E., May 10, 2024 at 11:35 am EDT
More quotes
4basebio PLC is a United Kingdom-based specialist life sciences company. It is focused on therapeutic deoxyribonucleic (DNA) for cell and gene therapies and DNA vaccines and providing solutions for effective and safe delivery of these DNA based products to patients. It is engaged in the manufacturing and supplying of application specific synthetic DNA for research, therapeutic and pharmacological use and develop non-viral vectors for the efficient delivery of payloads. It has technology in the fields of DNA synthesis and payload delivery, which enables it to manufacture both synthetic DNA constructs and messenger ribonucleic acid (mRNA) and develop vectors for cell and tissue-specific delivery for a range of applications. Its applications include AAV and Lentivirus viral vectors; mRNA vaccines and therapeutics, Genome editing; DNA vaccines, and Hermes non-viral delivery. It is also focused on exploiting intellectual property in the field of cell and gene therapies and DNA vaccines.
Calendar
2024-09-26
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +70.59% | 186M | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- 4BB Stock